Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck

Trial Profile

Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs Veliparib (Primary) ; Carboplatin; Cisplatin; Docetaxel; Fluorouracil; Hydroxycarbamide; Paclitaxel
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Nasopharyngeal cancer; Orofacial cancer; Oropharyngeal cancer; Salivary gland cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Results evaluating safety and efficacy of veliparib (n=18) were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2018 Status changed from completed to active, no longer recruiting.
    • 01 Jun 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top